Telomir Pharmaceuticals, Inc. filed a Form 8-K on November 18, 2026, disclosing that it has selected Linical as the contract research organization to support its FDA-cleared Phase 1/2 clinical trial of Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer.

Key Highlights

  • CRO Selected: Telomir Pharmaceuticals has chosen Linical, described in the filing as a global contract research organization with extensive oncology experience, to support the Phase 1/2 trial.
  • Trial Drug and Indication: The study evaluates Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC).
  • Regulatory Status: According to the filing, the Phase 1/2 clinical trial has been cleared by the U.S. Food and Drug Administration.
  • Agreements Executed: The company disclosed that it has executed a Master Services Agreement and a clinical trial Work Order with Linical.
  • Clinical Initiation Target: The filing states that clinical initiation is targeted for the first quarter of 2027, subject to the cautionary language described by the company.
  • Linical's Experience: The filing notes that Linical has more than two decades of oncology clinical development experience, with approximately half concentrated in early-phase studies.

Telomir Pharmaceuticals Engages Linical to Advance TNBC Study Toward Clinical Initiation

According to the Form 8-K filed with the SEC on November 18, 2026, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced its selection of Linical to serve as the contract research organization for the company's Phase 1/2 clinical trial. The trial is designed to evaluate Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer and has received clearance from the U.S. Food and Drug Administration, the filing disclosed.

The filing describes Linical as having oncology capabilities spanning Phase 1 through Phase 4 clinical development, encompassing clinical trial startup, investigator-site coordination, patient recruitment, clinical monitoring, project management, biometrics, and regulatory support. The company disclosed that approximately half of Linical's oncology experience is concentrated in early-phase studies, with coverage including breast cancer and other solid tumors.

As described in the filing, Telomir Pharmaceuticals has executed both a Master Services Agreement and a clinical trial Work Order with Linical, which the company said establishes "the operational framework to advance the study toward clinical initiation, targeted for the first quarter of 2027." The company noted that this report contains forward-looking statements subject to significant risks and uncertainties, as described in the cautionary language included in the filing, and that actual results could differ materially from those expressed or implied.

What Was Disclosed

Telomir Pharmaceuticals disclosed the selection of Linical as its CRO for an FDA-cleared Phase 1/2 trial of Telomir-Zn in TNBC patients, the execution of a Master Services Agreement and Work Order, and a targeted clinical initiation date in the first quarter of 2027.